| 货号 | 11981-5mg |
| 描述 | Pramipexole is an agonist of the Gαi-linked dopamine receptors D2, D3, and D4(Ki = 3.9, 2.2, 0.5, and 5.1 nM for D2S, D2L, D3, and D4, respectively).1,2,3 It is relatively inactive at the Gαs-linked dopamine receptors D1 and D5, as well as at serotonin and adrenergic receptors.1 This narrow profile of receptor binding distinguishes pramipexole from other compounds, particularly those derived from ergot fungi, which can be associated with adverse events when used for treating Parkinson’s disease and other disorders.1,4 Pramipexole undergoes almost no hepatic metabolism and exerts no potent inhibition of cytochrome P450 isoforms in vitro.1 |
| 别名 | Mirapex;SND 19; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Kvernmo, T.,Härtter, S., and Bürger, E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clinical Therapeutics 28(8), 1065-1078 (2006). 2.Millan, M.J.,Maiofiss, L.,Cussac, D., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303(2), 791-804 (2002). 3.Newman-Tancredi, A.,Cussac, D.,Audinot, V., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and α1/α2-adrenoceptor. Journal of Pharmacology and Experimental Therapeutics 303(2), 805-814 (2002). 4.Hametner, E.M.,Seppi, K., and Poewe, W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease. Clinical Interventions in Aging 7, 83-88 (2012). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 284.2 |
| 分子式 | C10H17N3S • 2HCl |
| CAS号 | 104632-25-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |